Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety Research of Endostar Combined With GDP to Treat Aggressive Peripheral T-cell Lymphoma (PTCL) in Phase II Clinical Study.

NCT02520219 is registered in ClinicalTrials.gov with Nanjing NingQi Medicine Science and Technology Co., Ltd. as lead sponsor.

NCT NCT02520219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02520219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety Research of Endostar Combined With GDP to Treat Aggressive Peripheral T-cell Lymphoma (PTCL) in Phase II Clinical Study.
Lead sponsor
Nanjing NingQi Medicine Science and Technology Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2014
Completion date
December 31, 2015
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t-cell lymphomas